Of Finance. To do so, we have implemented further measures to increase cost consciousness, which led to a company wide cost optimization and hence reduction of our expected 2023 R and D, SG and E spend and capital expenditures. The increased flexibility at expenditure level of Clinical Research and Development Solutions will help us navigate through the just described uncertainties, while remaining focused on the development of the next wave of innovation in various fields and indications. Of As summarized for you on this slide, we update our R and D spending for the rest of 2023 from between €2,400,000,000 and €2,600,000,000 to between €2,000,000,000 2,200,000,000 including the R and D development costs identified from our latest publicly announced M and A activities. We also update our SG and A expenses from between €650,000,000 to €750,000,000 now to between €600,000,000 €700,000,000 and reduce our spending for growth and maintenance CapEx for operating activities €500,000,000 €600,000,000 to between €350,000,000 €450,000,000 As noted before, we have Investor Relations.